Secondary Logo

Journal Logo

Most Popular Articles

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Bernier, Cynthia; Soliman, Ahmed; Gravel, Michel; More

Anti-Cancer Drugs. 29(8):774-785, September 2018.

Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic

Apostolatos, André H.; Apostolatos, Christopher A.; Ratnayake, Wishrawana S.; More

Anti-Cancer Drugs. 30(1):65-71, January 2019.

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer

Durairaj, Chandrasekar; Ruiz-Garcia, Ana; Gauthier, Eric R.; More

Anti-Cancer Drugs. 29(3):271-280, March 2018.

Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy

Mitani, Akihisa; Jo, Taisuke; Yasunaga, Hideo; More

Anti-Cancer Drugs. 29(6):560-564, July 2018.

Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network

Sanfilippo, Roberta; Dileo, Palma; Blay, Jean-Yves; More

Anti-Cancer Drugs. 26(6):678-681, July 2015.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin

Inagaki, Chiaki; Shimoi, Tatsunori; Okuma, Hitomi; More

Anti-Cancer Drugs. 29(1):97-101, January 2018.

Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study

Shi, Yuan-Kai; Chen, Qiang; Zhu, Yun-Zhong; More

Anti-Cancer Drugs. 24(6):641-647, July 2013.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models

Capasso, Anna; Pitts, Todd M.; Klauck, Peter J.; More

Anti-Cancer Drugs. 29(9):827-838, October 2018.

Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer

Leonard, Shannon C.; Lee, Helen; Gaddy, Daniel F.; More

Anti-Cancer Drugs. 28(10):1086-1096, November 2017.

Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

Romero, Ignacio; Mallol, Pedro; Santaballa, Ana; More

Anti-Cancer Drugs. 30(6):628-635, July 2019.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Franken, Margreet G.; Leeneman, Brenda; Jochems, Anouk; More

Anti-Cancer Drugs. 29(6):579-588, July 2018.

The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows

Di Vita, Maria; Cappellani, Alessandro; Piccolo, Gaetano; More

Anti-Cancer Drugs. 26(2):123-138, February 2015.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Jochems, Anouk; Leeneman, Brenda; Franken, Margreet G.; More

Anti-Cancer Drugs. 29(6):572-578, July 2018.

Determination of the maximal tumor:normal bladder ratio after i.p. or bladder administration of 5-aminolevulinic acid in Fischer 344 rats by fluorescence spectroscopy in situ

Bisson, Jean-François; Christophe, Marianne; Padilla-Ybarra, Juan-José; More

Anti-Cancer Drugs. 13(8):851-857, September 2002.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

Meerum Terwogt, Jetske M; van Tellingen, Olaf; Nannan Panday, Vinodh R; More

Anti-Cancer Drugs. 11(9):687-694, October 2000.

Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features

Balduzzi, Alessandra; Montagna, Emilia; Bagnardi, Vincenzo; More

Anti-Cancer Drugs. 20(3):197-203, March 2009.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

Meerum Terwogt, Jetske M; ten Bokkel Huinink, Wim W; Schellens, Jan HM; More

Anti-Cancer Drugs. 12(4):315-323, April 2001.

Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib

Numakura, Kazuyuki; Tsuchiya, Norihiko; Kagaya, Hideaki; More

Anti-Cancer Drugs. 28(1):97-103, January 2017.

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib

Ariyasu, Ryo; Horiike, Atsushi; Koyama, Junji; More

Anti-Cancer Drugs. 28(5):565-567, June 2017.

Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer

Rom, Joachim; Bechstein, Sarah; Domschke, Christoph; More

Anti-Cancer Drugs. 25(2):219-224, February 2014.